Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer

被引:113
作者
Jilg, Cordula A. [1 ]
Drendel, Vanessa [2 ]
Rischke, H. Christian [3 ,4 ]
Beck, Teresa [4 ]
Vach, Werner [5 ,6 ]
Schaal, Kathrin [1 ]
Wetterauer, Ulrich [1 ]
Schultze-Seemann, Wolfgang [1 ]
Meyer, Philipp T. [4 ,7 ]
机构
[1] Univ Freiburg, Fac Med, Med Ctr, Dept Urol, Freiburg, Germany
[2] Univ Freiburg, Fac Med, Inst Pathol, Freiburg, Germany
[3] Univ Freiburg, Fac Med, Med Ctr, Dept Radiat Oncol, Freiburg, Germany
[4] Univ Freiburg, Fac Med, Med Ctr, Dept Nucl Med, Freiburg, Germany
[5] Univ Freiburg, Fac Med, Inst Med Biometry & Stat, Freiburg, Germany
[6] Univ Freiburg, Med Ctr, Freiburg, Germany
[7] DKTK, German Canc Consortium, Partner Site Freiburg, Freiburg, Germany
来源
THERANOSTICS | 2017年 / 7卷 / 06期
关键词
prostate cancer; lymph node metastases; PSMA-PET/CT; salvage lymph node dissection; salvage lymphadenectomy; EAU GUIDELINES; PET/CT; LIGAND;
D O I
10.7150/thno.18421
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metastases directed therapies such as salvage-lymph node dissection (salvage-LND). Objective: To evaluate the diagnostic accuracy of PSMA-PET/CT for detection of affected lymph-node regions at salvage-LND for nodal recurrence of PCa. Design, setting and participants: 30 patients with the suspicion of exclusively nodal PCa-relapse after primary therapy underwent a template pelvic and/or retroperitoneal salvage-LND after whole body 68-Ga-PSMA-PET/CT. The diagnostic accuracy of PET/CT was evaluated in comparison to the histopathology of 965 resected lymph nodes (LN) dissected from 68 main regions (pelvic left/right, retroperitoneal) and 289 subregions (common iliac, external iliac, obturator, internal iliac, presacral, aortic-bifurcation, aortal, caval). LNM and tumor deposits in LNM were measured bidimensionally in the histopathology. PSMA-expression was analyzed by immunohistochemistry in LNM. Results: LNM were present in 11.4% of the resected LN (110/965) resulting in 45 positive main regions and 85 positive subregions. PET/CT was true positive in 41 main regions and 69 subregions. Three PET-negative main regions and 16 PET-negative subregions finally contained LNM, the majority of these false negative subregions (13/16) were in neighboring regions of true-positive subregions. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were: main region-based 93.2%, 100%, 100%, 88.9% and 95.6%, subregion-based 81.2%, 99.5%, 98.6%, 92.7 and 94.1%. Median short diameters of tumor deposits in LNM resected from false-negative subregions (1.3 mm) were significantly smaller than in LNM removed from true-positive subregions (5.5 mm, p<0.0001). Based on anatomical subregions containing just one LNM, the necessary short diameter of tumor deposits in LNM required to reach a detection rate of 50% and 90% was estimated to be >= 2.3 mm and >= 4.5 mm, respectively. Conclusion: In men with biochemical PCa-relapse and positive PSMA-PET/CT, PET/CT detects metastatic affected anatomical regions with high accuracy at a main region and at a subregion-level. If the decision for salvage-LND is prompted by a positive PSMA-PET/CT, the size of metastases is crucial for accurate detection of affected regions. All LNM showed a clear PSMA-expression in the immunohistochemistry. Further studies need to investigate how to translate the high anatomical correlation observed between PET/CT and surgical findings into optimal approaches for target salvage-LND.
引用
收藏
页码:1770 / 1780
页数:11
相关论文
共 23 条
  • [1] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
    Afshar-Oromieh, A.
    Malcher, A.
    Eder, M.
    Eisenhut, M.
    Linhart, H. G.
    Hadaschik, B. A.
    Holland-Letz, T.
    Giesel, F. L.
    Kratochwil, C.
    Haufe, S.
    Haberkorn, U.
    Zechmann, C. M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) : 486 - 495
  • [2] Afshar-Oromieh A, 2014, EUR J NUCL MED MOL I
  • [3] Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
    Afshar-Oromieh, Ali
    Zechmann, Christian M.
    Malcher, Anna
    Eder, Matthias
    Eisenhut, Michael
    Linhart, Heinz G.
    Holland-Letz, Tim
    Hadaschik, Boris A.
    Giesel, Frederik L.
    Debus, Juergen
    Haberkorn, Uwe
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) : 11 - 20
  • [4] Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy
    Budaeus, Lars
    Leyh-Bannurah, Sami-Ramzi
    Salomon, Georg
    Michl, Uwe
    Heinzer, Hans
    Huland, Hartwig
    Graefen, Markus
    Steuber, Thomas
    Rosenbaum, Clemens
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 393 - 396
  • [5] Gleason Score at Diagnosis Predicts the Rate of Detection of 18F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients
    Cimitan, Marino
    Evangelista, Laura
    Hodolic, Marina
    Mariani, Giuliano
    Baseric, Tanja
    Bodanza, Valentina
    Saladini, Giorgio
    Volterrani, Duccio
    Cervino, Anna Rita
    Gregianin, Michele
    Puccini, Giulia
    Guidoccio, Federica
    Fettich, Jure
    Borsatti, Eugenio
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 209 - 215
  • [6] Deutsche Krebsgesellschaft DK AWMF, 2016, KONS INT LEITL QUAL
  • [7] Novel Preclinical and Radiopharmaceutical Aspects of [Ga-68]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
    Eder, Matthias
    Neels, Oliver
    Mueller, Miriam
    Bauder-Wust, Ulrike
    Remde, Yvonne
    Schaefer, Martin
    Hennrich, Ute
    Eisenhut, Michael
    Afshar-Oromieh, Ali
    Haberkorn, Uwe
    Kopka, Klaus
    [J]. PHARMACEUTICALS, 2014, 7 (07): : 779 - 796
  • [8] Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
    Eiber, Matthias
    Maurer, Tobias
    Souvatzoglou, Michael
    Beer, Ambros J.
    Ruffani, Alexander
    Haller, Bernhard
    Graner, Frank-Philipp
    Kuebler, Hubert
    Haberhorn, Uwe
    Eisenhut, Michael
    Wester, Hans-Juergen
    Gschwend, Juergen E.
    Schwaiger, Markus
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) : 668 - 674
  • [9] EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
    Heidenreich, Axel
    Bastian, Patrick J.
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    van der Kwast, Theodor
    Mason, Malcolm
    Matveev, Vsevolod
    Wiegel, Thomas
    Zattoni, Filiberto
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2014, 65 (02) : 467 - 479
  • [10] EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013
    Heidenreich, Axel
    Bastian, Patrick J.
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    van der Kwast, Theodor
    Mason, Malcolm
    Matveev, Vsevolod
    Wiegel, Thomas
    Zattoni, F.
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2014, 65 (01) : 124 - 137